EIB provides funding to Jennewein

Rheinbreitbach (ots) - The European Investment Bank (EIB) provides
new financing of EUR 15 million to Jennewein Biotechnologie GmbH, a
highly innovative German company that offers a breakthrough
technology for the production of rare functional sugars for a wide
range of applications, including nutritional, pharmaceutical and
cosmetic products. The Company is also a leading manufacturer of
human milk oligosaccharides (HMOs), which form an essential part of
human mother milk and have been shown to have beneficial health
impacts.

The EU bank's loan is backed by a guarantee from the European Fund
for Strategic Investments (EFSI). EFSI is an essential pillar of the
Investment Plan for Europe - also known as the Juncker Plan - under
which the EIB and the European Commission are working together as
strategic partners and the EIB's financing operations are boosting
the competitiveness of the European economy.

The President of the European Investment Bank, Werner Hoyer,
stated: "The EU bank supports in Europe many activities which by
nature are riskier and therefore often face difficulties in accessing
finance. We, as the EU bank, can provide these funds to address the
needs of small and innovative companies, as we are backed by the
European Fund for Strategic Investments. This clearly demonstrates
the added value that the Juncker-Plan brings to the European economy
to foster growth and jobs."

Jennewein will use the new financing to build a R&D centre to
continue increasing its HMO's product portfolio. It also will upscale
its production capacity. Stefan Jennewein, founder and CEO of
Jennewein, emphasised that being on a new and very innovative market,
commercial banks were not prone to invest in his business while the
EIB was there to make sure his development plans come true." With
this loan the European Investment Bank has given us her trust and the
chance to conquer furthermore the market of human milk
oligosaccharides. With the help of the EIB we can invest in the
future, it means in our production and a new R&D research center"
says Stefan Jennewein on the occasion of signing the contract in
Rheinbreitbach.

European Commissioner Vytenis Andriukaitis said: ''As the EU
Commissioner for Health and Food Safety and a former doctor, I know
the positive impact that research, innovation, including in
biotechnology, can have on our nutrition and good health,
particularly those of infants and young children. I am happy to see
that the Investment Plan for Europe is really working and boosts
research and innovation for the health of EU citizens."

European Investment Bank

The European Investment Bank (EIB) is the long-term lending
institution of the European Union, owned by its Member States. It
makes long-term finance available for sound investment in order to
contribute towards EU policy goals.

About Jennewein

Jennewein Biotechnologie is a leading international industrial
biotechnology company with a range of products in the field of
complex oligosaccharides (HMOs) and rare monosaccharides. The company
manufactures an extensive portfolio of innovative HMO products, such
as 2?fucosyllactose, 3?-fucosyllactose and lacto-N-tetraose. These
rare sugars are used in the food industry (particularly infant milk
formulas), the pharmaceutical industry, and the cosmetic industry. In
2015, the US Food and Drug Administration (FDA) granted Jennewein
Biotechnologie a license to market 2?-fucosyllactose in the USA. This
was followed in 2017 by European Union marketing authorisation under
the Novel Food Regulation.

Originaltext: Jennewein Biotechnologie GmbH
digital press kits: http://www.presseportal.de/nr/77411
press kits via RSS: http://www.presseportal.de/rss/pm_77411.rss2

Contact:
Dr. Bettina Gutiérrez,
[e-mail]
Tel.:[phone]